I. Coleman

Differential response to LSD1 inhibition in prostate cancer reveals a YAP1 vulnerability in the neuroendocrine subtype

This paper shows that LSD1 inhibition is effective against neuroendocrine prostate cancer (NEPC) and that combining it with YAP/TEAD inhibition enhances treatment efficacy.

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer

This study identifies biomarkers beyond B7H3 expression that predict response to a B7H3-ADC in metastatic prostate cancer models, improving therapeutic efficacy.

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer

This study identifies two distinct subtypes of neuroendocrine prostate cancer based on neuronal transcription factors and highlights their epigenetic convergence and therapeutic implications.

Targeting RET Kinase in Neuroendocrine Prostate Cancer

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.

EZH2 co-opts gain-of-function p53 mutants to promote cancer growth and metastasis

This study identifies EZH2 as a p53 mRNA-binding protein that enhances translation of gain-of-function p53 mutants, promoting cancer growth and metastasis, and shows that inhibiting EZH2 causes synthetic lethality in these cells.